Navigation Links
AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer

NEW YORK, Oct. 16 /PRNewswire-FirstCall/ -- AngioGenex Inc. (OTC Bulletin Board: AGGX.OB) has identified and filed a patent application on small molecules that are potent inhibitors of the Id proteins. "The identification of these lead molecules and the filing of this patent constitute major milestones in the Company's goal to develop orally active anti-cancer drugs," said Dr. Richard Salvador, President and CEO, and the former global head of Preclinical Development at Hoffmann La Roche, Inc. He further stated that, "the work embodied in this patent establishes the 'drugability' of the Id proteins as targets allowing the Company to move forward with the preclinical work required to bring these molecules into the clinic."

According to Dr. William Garland, VP & Head of R&D, "both the in vitro and in vivo studies indicate that our small molecule inhibitors of the Id proteins will block angiogenesis and malignant transformation of cells responsible for tumor growth in man, and are likely to be orally active." Further, "inhibition of the Id proteins by these small molecules is unlikely to cause serious adverse effects in patients since they are not known to be required for the normal function of cells of the body. Their only function, with minor exceptions, is to promote blood vessel formation into tumors."

AngioGenex is currently testing a companion diagnostic that detects low levels of the Id proteins in serum. This diagnostic was developed in collaboration with BioCheck, Inc. of Foster City, California. Preliminary clinical results suggest that it has the potential to detect the presence of Id proteins at an early stage of tumor development allowing early medical intervention; it may also be useful to either follow the course of therapy or to determine whether there is a recurrence of disease.

AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer molecules that act by inhibiting either the Id genes or proteins to prevent the formation of new blood vessels into tumors (angiogenesis). The Company's technology is based on the research of Dr. Robert Benezra and his colleagues at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City who established that activation of the Id genes is required for the formation of new blood vessels into tumors, allowing tumors to grow and metastasize. Dr. Benezra demonstrated that the absence of the Id genes in animals results in a highly significant inhibition of tumor growth and a reduction in the size of mature tumors. The research of Dr. Benezra on the role of the Id genes in tumor formation has been widely recognized for its important therapeutic implications.

This press release may contain forward-looking statements that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the ability of AngioGenex to raise subsequent, substantial additional financing, to complete clinical development of AngioGenex products, and the ability of the Company to successfully develop and market AngioGenex products and technologies. These statements represent the judgment of management as of this date and are subject to risks and uncertainties that could materially affect the Company. AngioGenex undertakes no obligation to publicly release the results of any revisions to such forward-looking statements that may be made to reflect recent events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE AngioGenex Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
5. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
6. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
10. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
11. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening to conquer ... in advanced audiology and hearing aid technology, has today ... world,s first internet connected hearing aid that opens up ...      (Photo: ) , ... , TwinLink™ - the first dual communication ...
(Date:6/23/2016)... June 23, 2016  Experian Health, the ... transforming the patient payment and care experience, ... new products and services that will enhance ... cycle offerings. These award-winning solutions will enable ... remain compliant in an ever-changing environment and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
Breaking Medicine News(10 mins):